USP17L2 and colorectal carcinoma: Notably, we demonstrated that the inhibitory effects of abemaciclib on YAP1 stability and YAP1‐driven tumor progression are largely mediated by DUB3, a previously unidentified deubiqutinase of YAP1 in CRC.